Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
NCT02460367 · NewLink Genetics Corporation · PHASE1 · terminated · last registry update 2022-04-06 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of enrollment and changing landscape of standard of care.” | Open Targets' class: insufficient enrollment, study design | Registry record, NewLink Genetics Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTOR in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision